AusCann Group Holdings Limited announced it has completed manufacturing and testing of its proprietary cannabinoid-based hard-shell capsules and released the hard-shell capsules for clinical evaluation. The Company is working to develop a commercially focused, short clinical evaluation. AusCann's solid- fill capsule formulation is a unique presentation for cannabinoid medicines, and the clinical evaluation goal is to provide key exposure information to inform dose selection. The Company will inform the market once the clinical evaluation commences. The hard-shell capsules were tested according to standardised validated tests used across the pharmaceutical industry to ensure product quality prior to release of products to market. The hard-shell capsules were tested and found to meet all applicable pre-defined criteria set by the Australian Therapeutic Goods Administration (TGA), relevant International Pharmacopoeial standards and AusCann's quality assurance and control procedures. The release of the capsules validates AusCann as a commercial producer of reliable, stable and standardised pharmaceutical products: Reliable: Consistently producing dose-controlled capsules which enable controlled dose titrations and informed monitoring of health outcomes. The test results validate dose reliability for every capsule, assuring that each dose is true to label; Stable: Since cannabinoids tend to degrade over time when not adequately protected, AusCann products were designed to ensure that the capsules perform consistently throughout the shelf life of the product. The product design and testing completed confirms the hard-shell capsules' unique formulation will remain stable up to the expiry date of the product; Standardised: AusCann's products comply with validated quality control standards used internationally to ensure quality of pharmaceutical products prescribed by doctors; An accelerated path to commercialisation ­ following all positive test results, AusCann will now progress with an accelerated path to commercialisation. AusCann will supply products to physicians where approved under the Therapeutic Goods Administration Special Access Scheme and Authorised Prescriber Scheme. These programs are based in Australia. AusCann is targeting hard-shell capsules availability for patients in Australia during the first half of CY 2020.